{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:07:21Z","timestamp":1745035641201,"version":"3.40.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clindermatol.2024.12.006","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:02:00Z","timestamp":1734372120000},"page":"170-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies"],"prefix":"10.1016","volume":"43","author":[{"given":"Madisen A.","family":"Swallow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Edelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"Hachette Livre","year":"1806","author":"Alibert","key":"10.1016\/j.clindermatol.2024.12.006_bib0001"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0002","first-page":"257","article-title":"\u00c0 propos d'un aspect histopathologique nouveau d'un ganglion lymphatique: la r\u00e9ticulose lipom\u00e9lanique","author":"Pautrier","year":"1937","journal-title":"Ann Dermatol Syphil"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0003","first-page":"257","article-title":"Erythroderma with presence of monstrous cells in the dermis and circulating in blood","author":"Sezary","year":"1937","journal-title":"Ann Dermatol Syphyil"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0004","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-80-6-685","article-title":"Preferential cutaneous infiltration by neoplastic thymus-derived lymphocytes. Morphologic and functional studies","volume":"80","author":"Edelson","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0005","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1172\/JCI108585","article-title":"The Sezary syndrome: a malignant proliferation of helper T cells","volume":"58","author":"Broder","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0190-9622(88)70147-4","article-title":"Progression of pigmented purpura-like eruptions to mycosis fungoides: report of three cases","volume":"19","author":"Barnhill","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0007","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0190-9622(95)91337-8","article-title":"Hypopigmented variant of mycosis fungoides: demography, histopathology, and treatment of seven cases","volume":"32","author":"Lambroza","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0008","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/1097-0142(19930401)71:7<2335::AID-CNCR2820710727>3.0.CO;2-D","article-title":"Cyclosporine treatment of refractory T-cell lymphomas","volume":"71","author":"Cooper","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0009","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0190-9622(84)70030-2","article-title":"Photochemotherapy for cutaneous T cell lymphoma. A follow-up study","volume":"10","author":"Honigsmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0190-9622(87)70005-X","article-title":"Electron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation","volume":"16","author":"Braverman","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0011","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0190-9622(87)70004-8","article-title":"Combined total body electron beam irradiation and chemotherapy for mycosis fungoides","volume":"16","author":"Braverman","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0013","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0014","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: Multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0015","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0016","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0017","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0018","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0019","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0020","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0021","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jama.286.9.1020","article-title":"Use of fine art to enhance visual diagnostic skills","volume":"286","author":"Dolev","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0022","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0023","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jid.2023.10.018","article-title":"Deciphering tumor cell evolution in cutaneous T-cell lymphomas: distinct differentiation trajectories in mycosis fungoides and sezary syndrome","volume":"144","author":"Jiang","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0024","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/cells12121616","article-title":"Is cutaneous T-cell lymphoma caused by ultraviolet radiation? a comparison of UV mutational signatures in malignant melanoma and mycosis fungoides","volume":"12","author":"Gniadecki","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/bloodadvances.2022008168","article-title":"Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations","volume":"7","author":"Ren","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.seminhematol.2021.02.002","article-title":"Novel therapies targeting cutaneous T cell lymphomas and their microenvironment","volume":"58","author":"Reneau","year":"2021","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0027","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0028","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and Sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0029","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0030","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0031","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of Sezary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0032","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jid.2016.03.024","article-title":"Identification of gene mutations and fusion genes in patients with sezary syndrome","volume":"136","author":"Prasad","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0033","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in Sezary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0034","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.jid.2018.06.176","article-title":"An integrated data resource for genomic analysis of cutaneous T-cell lymphoma","volume":"138","author":"Chang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0035","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0036","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.968395","article-title":"CAR-T cell development for cutaneous T cell lymphoma: current limitations and potential treatment strategies","volume":"13","author":"To","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0038","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fonc.2019.00259","article-title":"CAR-based approaches to cutaneous T-Cell Lymphoma","volume":"9","author":"Scarfo","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0039","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0040","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/bloodadvances.2022008798","article-title":"TCRv\u03b2-CART therapy mediates high-precision targeting of malignant T-cell clones","volume":"7","author":"Shaw","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0041","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1038\/s41467-022-32092-8","article-title":"T cell receptor beta-chain-targeting chimeric antigen receptor T cells against T cell malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0042","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41467-024-44786-2","article-title":"Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vbeta2+ T cell malignancy","volume":"15","author":"Ren","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0043","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","article-title":"Naturally occurring T cell mutations enhance engineered T cell therapies","volume":"626","author":"Garcia","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0044","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s11912-023-01464-8","article-title":"What is new in cutaneous T cell lymphoma?","volume":"25","author":"Morgenroth","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0045","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","article-title":"Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0046","doi-asserted-by":"crossref","first-page":"eabd3595","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR beta chain-directed bispecific antibodies for the treatment of T cell cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0047","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0048","doi-asserted-by":"crossref","first-page":"29193","DOI":"10.18632\/oncotarget.25670","article-title":"BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition","volume":"9","author":"Kim","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0049","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/bloodadvances.2020001756","article-title":"JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL","volume":"4","author":"Yumeen","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0050","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jid.2022.12.017","article-title":"Proteasome inhibitors interact synergistically with BCL2, histone deacetylase, BET, and Jak inhibitors against cutaneous T-cell lymphoma Cells","volume":"143","author":"Xu","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0051","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1016\/j.jid.2022.06.005","article-title":"The robust tumoricidal effects of combined BET\/HDAC inhibition in cutaneous T-cell lymphoma can be reproduced by DeltaNp73 depletion","volume":"142","author":"Zhao","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0052","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jid.2018.03.197","article-title":"192 Gene expression profiling of mechlorethamine and romidepsin combination shows downregulation of the JAK\/STAT pathway in cutaneous T-cell lymphoma","volume":"138","author":"Patrone","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0053","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma","volume":"82","author":"Heider","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clindermatol.2024.12.006_bib0054","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/15384047.2016.1219820","article-title":"The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines","volume":"17","author":"Cosenza","year":"2016","journal-title":"Cancer Biol Ther"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X24002712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X24002712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T14:32:28Z","timestamp":1744986748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X24002712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0738081X24002712"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2024.12.006","relation":{},"ISSN":["0738-081X"],"issn-type":[{"type":"print","value":"0738-081X"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}